Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023
DOI:
https://doi.org/10.2340/1651-226X.2024.34139Keywords:
Ovarian, cancer, HRD, biomarker, Myriad, PARPi, BRCAAbstract
Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.
Materials and methods: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from ovarian and breast cancer samples submitted for HRD-testing by myChoice® CDx through the Nordic core facility in the 2-year period.
Results: Copenhagen University Hospital received 1,948 requisitions during the 2-year period. Conclusive results were obtained in 89% of the tests, while 7% were inconclusive due to the lack of GIS and 4% were not able to be analysed. Comparing the conclusive HRD status results across countries, Sweden had the highest percentage of HRD positives (38%) compared to Denmark, Norway, and Finland (28–32%).
Interpretation: The myChoice® CDx Nordic core facility has been well received among the Nordic countries and provides new insights on the influence of national guidelines on HRD testing. Overall, we experienced an efficient turnaround time and a high fraction of conclusive results. Interestingly, prior somatic BRCA testing is redundant when assessing HRD status through myChoice® CDx test since somatic BRCA screening is already a significant component of the myChoice® CDx test. Thus, it should be considered to omit prior somatic BRCA testing to ensure a rationalised HRD diagnostic flow optimised for clinical use.
Downloads
References
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. https://doi.org/10.1038/nature03443 DOI: https://doi.org/10.1038/nature03443
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445 DOI: https://doi.org/10.1038/nature03445
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. https://doi.org/10.1056/NEJMoa1105535 DOI: https://doi.org/10.1056/NEJMoa1105535
Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer. Ann Rev Cancer Biol. 2018;2:313–36. https://doi.org/10.1146/annurev-cancerbio-030617-050502 DOI: https://doi.org/10.1146/annurev-cancerbio-030617-050502
Iglehart JD, Silver DP. Synthetic lethality – a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189–91. https://doi.org/10.1056/NEJMe0903044 DOI: https://doi.org/10.1056/NEJMe0903044
Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152–8. https://doi.org/10.1126/science.aam7344 DOI: https://doi.org/10.1126/science.aam7344
Banerjee S, Gonzalez-Martin A, Harter P, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open – Cancer Horizons round-table discussion. ESMO Open. 2020;5(6):e001110. https://doi.org/10.1136/esmoopen-2020-001110 DOI: https://doi.org/10.1136/esmoopen-2020-001110
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15. https://doi.org/10.1158/0008-5472.CAN-06-0140 DOI: https://doi.org/10.1158/0008-5472.CAN-06-0140
Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962 DOI: https://doi.org/10.1056/NEJMoa1910962
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416–28. https://doi.org/10.1056/NEJMoa1911361 DOI: https://doi.org/10.1056/NEJMoa1911361
Westphalen CB, Fine AD, Andre F, et al. Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score. Clin Cancer Res. 2022;28(7):1412–21. https://doi.org/10.1158/1078-0432.CCR-21-2096 DOI: https://doi.org/10.1158/1078-0432.CCR-21-2096
Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73. https://doi.org/10.1158/1078-0432.CCR-15-2477 DOI: https://doi.org/10.1158/1078-0432.CCR-15-2477
Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV. Preventing and overcoming resistance to PARP inhibitors: a focus on the clinical landscape. Cancers (Basel). 2021;14(1):14. https://doi.org/10.3390/cancers14010044 DOI: https://doi.org/10.3390/cancers14010044
Stewart MD, Merino Vega D, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27(3):167–74. https://doi.org/10.1093/oncolo/oyab053 DOI: https://doi.org/10.1093/oncolo/oyab053
Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062 DOI: https://doi.org/10.1093/annonc/mdz062
Vergote I, Gonzalez-Martin A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33(3):276–87. https://doi.org/10.1016/j.annonc.2021.11.013 DOI: https://doi.org/10.1016/j.annonc.2021.11.013
Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606–22. https://doi.org/10.1016/j.annonc.2020.08.2102 DOI: https://doi.org/10.1016/j.annonc.2020.08.2102
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Lea Milling Korsholm, Verena Broecker, Mansoor Raza Mirza, Maria Rossing
This work is licensed under a Creative Commons Attribution 4.0 International License.
